(NASDAQ: GOSS) Gossamer Bio's forecast annual revenue growth rate of -21.47% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.91%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.44%.
Gossamer Bio's revenue in 2024 is $95,842,000.On average, 5 Wall Street analysts forecast GOSS's revenue for 2024 to be $23,317,017,358, with the lowest GOSS revenue forecast at $21,681,620,503, and the highest GOSS revenue forecast at $25,541,057,541. On average, 4 Wall Street analysts forecast GOSS's revenue for 2025 to be $5,437,598,397, with the lowest GOSS revenue forecast at $3,290,927,937, and the highest GOSS revenue forecast at $9,411,053,974.
In 2026, GOSS is forecast to generate $14,322,900,222 in revenue, with the lowest revenue forecast at $3,772,113,317 and the highest revenue forecast at $34,746,244,710.